144 related articles for article (PubMed ID: 28508247)
21. Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts.
Heim C; Eckl S; Preidl R; Ramsperger-Gleixner M; Koch N; Goldmann K; Spriewald BM; Weyand M; Ensminger SM
Eur J Cardiothorac Surg; 2015 Jan; 47(1):180-7. PubMed ID: 24674907
[TBL] [Abstract][Full Text] [Related]
22. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
[TBL] [Abstract][Full Text] [Related]
23. Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses.
Levitsky J; Miller J; Huang X; Gallon L; Leventhal JR; Mathew JM
PLoS One; 2016; 11(6):e0156535. PubMed ID: 27275747
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus.
Poncelet AJ; Nizet Y; Vercruysse J; Hiel AL; Saliez A; Gianello P
Transplantation; 2008 Dec; 86(11):1586-95. PubMed ID: 19077894
[TBL] [Abstract][Full Text] [Related]
25. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus.
Demmers MW; Baan CC; Janssen M; Litjens NH; Ijzermans JN; Betjes MG; Weimar W; Rowshani AT
Transplantation; 2014 Jan; 97(1):47-55. PubMed ID: 24157471
[TBL] [Abstract][Full Text] [Related]
26. Everolimus: a guide to its use in liver transplantation.
Keating GM; Lyseng-Williamson KA
BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
[TBL] [Abstract][Full Text] [Related]
27. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.
Reinders ME; Bank JR; Dreyer GJ; Roelofs H; Heidt S; Roelen DL; Al Huurman V; Lindeman J; van Kooten C; Claas FH; Fibbe WE; Rabelink TJ; de Fijter JW
J Transl Med; 2014 Dec; 12():331. PubMed ID: 25491391
[TBL] [Abstract][Full Text] [Related]
28. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus.
Cortina G; Trojer R; Waldegger S; Schneeberger S; Gut N; Hofer J
Pediatr Nephrol; 2015 Apr; 30(4):693-7. PubMed ID: 25577332
[TBL] [Abstract][Full Text] [Related]
29. Thirty Years of Tacrolimus in Clinical Practice.
Ong SC; Gaston RS
Transplantation; 2021 Mar; 105(3):484-495. PubMed ID: 32541562
[TBL] [Abstract][Full Text] [Related]
30. Action profiles of statins and calcineurin inhibitors during human mixed lymphocyte reaction.
Takahashi HK; Iwagaki H; Yagi T; Kanke T; Liu K; Yoshino T; Tanaka N; Nishibori M
Clin Immunol; 2007 Jun; 123(3):324-32. PubMed ID: 17482516
[TBL] [Abstract][Full Text] [Related]
31. Everolimus and sirolimus antagonize tacrolimus based calcineurin inhibition via competition for FK-binding protein 12.
van Rossum HH; Romijn FP; Smit NP; de Fijter JW; van Pelt J
Biochem Pharmacol; 2009 Apr; 77(7):1206-12. PubMed ID: 19154728
[TBL] [Abstract][Full Text] [Related]
32. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients.
Lemaitre F; Antignac M; Fernandez C
Clin Biochem; 2013 Oct; 46(15):1538-41. PubMed ID: 23454394
[TBL] [Abstract][Full Text] [Related]
36. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
38. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens.
Millán O; Jiménez O; Fortuna V; Barceló JJ; Brunet M
Int J Immunopathol Pharmacol; 2006; 19(2):317-30. PubMed ID: 16831299
[TBL] [Abstract][Full Text] [Related]
39. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.
Bocian K; Borysowski J; Wierzbicki P; Wyzgal J; Klosowska D; Bialoszewska A; Paczek L; Górski A; Korczak-Kowalska G
Nephrol Dial Transplant; 2010 Mar; 25(3):710-7. PubMed ID: 19903662
[TBL] [Abstract][Full Text] [Related]
40. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
